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INTRODUCTION 
Malaria is the world’s most ravaging infectious disease. Rampant throughout 
much of the tropics and some of the temperate areas, its numbers beggar the 
imagination. It threatens a third of the world’s population, presently afflicts 
hundreds of millions of people, causes several million deaths annually and may 
generate as many as 92 million new clinical cases each year [ 1, 21. Its socio- 
economic drain is enormous. 
The resurgence of this pestilence during the past two decades has stimulated 
the search for a vaccine but, despite a prodigious research effort and some 
cautious optimism, an effective vaccine is still far from fruition [3-lo]. In the 
interim, there must be continued reliance on drugs for prophylaxis and therapy. 
Research leading to the currently available antimalarial agents has been detailed 
in a number of comprehensive reviews [ 11-29]. Unfortunately, most of these 
agents are obsolescent because of the facility with which the malarial parasite 
produces drug-resistant mutants [ 301. The need for more effective antimalarials 
is therefore critical. In a search for such drugs, a small group of investigators 
has returned to an old, very heavily worked and seemingly exhausted mine, the 
8-aminoquinolines. The evolution of an extremely promising series of new, 
broad-spectrum, antimalarial 8-aminoquinolines is described in this chapter. 
The new drugs are unique in their dual efficacy against the blood and tissue 
forms of the disease. 
THE PARASITE 
Malaria is caused by protozoan parasites of the genus Plasmodium. There are 
four species of Plasmodia pathogenic to man: P. falciparum (malignant tertian 
malaria), P. v i v a  (benign tertian malaria), P. malariae (quartan malaria) and 
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P. ovule. P. falciparum and P. vivax, together, cause 95% of human malaria. 
P. ovule, the rarest of the four species, occurs mainly in West Africa and is much 
like P. vivax. P. malariae causes a generally mild but extraordinarily tenacious 
form of the disease which can persist in the blood, with or without symptoms, 
for a lifetime. 
The life cycle of the parasite has three phases: exoerythrocytic (tissue) and 
erythrocytic (blood) in man; sporogony in the mosquito. 
EXOERYTHROCYTIC PHASE 
Each species begins its cycle with the injection of thread-like, motile organisms 
(sporozoites) into the host's bloodstream during the bite of an infected female 
anopheles mosquito. Within an hour, the sporozoites leave the bloodstream, 
enter the liver and invade hepatocytes. Most of the sporozoites develop into 
primary tissue schizonts (schizogony) which undergo repeated asexual division 
to form thousands of merozoites. At maturity, the merozoites burst from the 
hepatocytes into the bloodstream, attack red blood cells and begin the erythro- 
cytic phase of the cycle. Some of the sporozoites of P. vivax and P. ovale remain 
in the liver as latent forms called hypnozoites [31]. The hypnozoites become 
active intermittently, for years, releasing new merozoites into cleared blood and 
causing relapses. P. falciparum and P. malariae have no hypnozoite stage and, 
therefore, no potential for relapse. 
ERYTHROCYTIC PHASE 
On invading an erythrocyte, the merozoite assumes a ring shape called a 
trophozoite and begins to feed on haemoglobin. The globin fraction is 
metabolized and the haem fraction is deposited in the tissues as granules called 
haemozoin or malaria pigment. When the trophozoite matures and begins to 
divide, it becomes a blood schizont. Division continues causing cell lysis and 
the discharge of new merozoites which invade fresh red cells for another 
asexual cycle. It is the periodic rupture of erythrocytes, with the expulsion of 
merozoites, their waste products and cellular debris, which is responsible for 
the paroxysmal nature of malaria. Some of the merozoites enter red cells and 
develop into trophozoites but form no schizonts. Instead, their nuclei remain 
intact and they differentiate into sexual forms, male and female, known as 
gametocytes. The gametocytes undergo no further development in man but 
circulate in the bloodstream until ingested during an anopheline blood meal. 
4 ANTIMALARIAL ACTIVITY OF 8-AMINOQUINOLINES 
SPOROGONY 
In the mosquito midgut, all stages of the parasite except the gametocytes are 
destroyed. On maturation, the sperm-like male (microgamete) fertilizes the 
egg-like female (macrogamete) forming a zygote. The zygote becomes a motile, 
saclike structure called an ookinete which penetrates the stomach wall and 
forms an oocyst beneath the wall’s outer membrane. Development of the oocyst 
leads to the formation of large numbers of infectious sporozoites which escape 
and migrate to the mosquito’s salivary glands. With the insect’s next bite, the 
parasite’s life cycle is renewed. Sporogony takes from 2 to 3 weeks, depending 
on the species. 
THE DISEASE 
Malaria becomes manifest with a general malaise followed by a series of 
recurrent, three-stage paroxysms of shaking chills, a temperature which can rise 
as high as 106°F and a drenching sweat. The paroxysms, which signal the 
completion of each asexual cycle, can recur at regular intervals - about 48 h 
for P. vivux, P. ovule and P. fulcipurum and about 72 h for P. malariue. With the 
non-falciparum malarias, some degree of immunity eventually develops, para- 
sitemia is diminished and, despite relapses and considerable debilitation, death 
is uncommon, even without treatment. However, an untreated falciparum 
infection frequently leads to a fulminating, pathophysiologic cascade (non- 
responsive hypotension ; anaemia, hyperpyrexia; hypoglycaemia; lactic acido- 
sis ; fluid and electrolyte disturbances ; septicemia; hemoglobinuria; pulmonary 
oedema; failure of hepatic, cerebral and renal function; shock; coma) and 
death may occur soon after onset of symptoms [ 32,331. The mortality rate from 
the cerebral form of severe falciparum malaria may be as high as 50% [34]. 
It is mainly the rapid geographic spread of extremely dangerous, multi-drug- 
resistant P. fulcipurum which makes the need for new antimalarial drugs so 
urgent. 
CLASSIFICATION OF ANTIMALARIAL DRUGS 
The aim of antimalarial chemotherapy is a cheap, safe, stable drug which could 
be administered in a single, well-tolerated, long-lasting, oral dose and which 
would interrupt all of the stages in the parasite’s life cycle without the selection 
of resistant strains. No such drug exists. Because of their relatively narrow 
activity spectra, the presently available antimalarials are classified according to 
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their mode of attack. Thus, drugs which destroy the intrahepatic parasites, 
before their emergence into the circulation, are termed pre-erythrocytic or 
primary tissue schizontocides or causal prophylactics. True prophylactics, 
which would act on the sporozoites during the brief interval between anopheline 
injection and hepatic sequestration, are unknown. Destruction of the asexual 
blood forms of the relapsing malarias, with the resulting elimination of clinical 
symptoms, is effected by agents called suppressive drugs or blood schizonto- 
cides. However, complete elimination of the relapsing malarias (radical cure) 
requires a second drug which can eradicate the persistent liver forms. Such 
drugs are known variously as radically curative drugs, antirelapse agents, 
secondary tissue schizontocides or hypnozoitocides. Radical cure of malariae 
and falciparum malaria, which have no persistent liver forms, can be achieved 
with blood schizontocides. The parasites may also be attacked during their 
sexual development in the host (gametocytocide) or mosquito (sporontocide), 
thereby preventing transmission. 
The most pressing present needs in malaria chemotherapy are a safe anti- 
relapse drug and a blood schizontocide which can eliminate resistant 
P. falciparurn without selecting new troublesome mutants. Thus far, there is no 
single clinical drug which can carry out both functions. Among the drugs and 
drug combinations in current use as blood schizontocides are chloroquine, 
amodiaquine, amopyroquine, quinine, proguanil, chlorproguanil, cycloguanil, 
pyrimethamine, trimethoprim, sulfadoxine, sulfalene, dapsone, mefloquine, 
halofantrine, qinghaosu and its derivatives, doxycycline, tetracycline, pyri- 
methamine-sulfadoxin (Fansidar), pyrimethamine-sulfadoxine-mefloquine 
(Fansimef), pyrimethamine-sulfadoxine-amodiaquine, pyrimethamine-dap- 
sone (Maloprim), quinine-quinidine-cinchonine (Falcimax) and quinine-tetra- 
cycline. In stark contrast, there are presently only two drugs in clinical use as 
tissue schizontocides (radical curative or antirelapse drugs); those drugs are the 
8-aminoquinolines, primaquine and, to a lesser extent, quinocide. 
HISTORY 
The germinal work in the evolution of primaquine occurred a century ago when 
Guttmann and Ehrlich treated malaria with methylene blue (1) after noting the 
dye’s selective staining of intraerythrocytic plasmodia in vitro [ 351. Schulemann 
and colleagues subsequently found that the activity of methylene blue could be 
improved by substituting the basic dialkylaminoalkyl chain, -(CH,),NEt,, for 
one of the dye’s methyl groups to give compound (2) [36]. After attachment 
to a number of diverse structures, the chain found its way to an 8-aminoquino- 
line producing the avian antimalarial (3) [37]. The activity of (3), and 
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(1)  R = M e  
(2) R = (CH2I2NEt2 
( 3 )  
Germany’s need to find a substitute for the quinine interdicted by World War 
I, triggered a massive investigation of the 8-aminoquinolines which led through 
thousands of variants to the first practical synthetic antimalarial, pamaquine 
(4) [38-451. Most of the original German research was never published and, 
despite some interesting detective work by Steck [ 141, the exact sequence, from 
methylene blue in 1891 to pamaquine in 1926, remains somewhat nebulous. 
Unfortunately, the early enthusiasm for pamaquine’s ability to cure vivax 
infections [46-481 was soon tempered by the frequency with which it caused 
methaemoglobinemia and acute haemolytic anaemia [ 141. When World War 
I ended, research on the 8-aminoquinolines became less intense [49-581 and 
at the beginning of World War 11, pamaquine was still the only antirelapse drug 
known. When malaria’s terrible toll on military personnel created an urgent 
need for an antirelapse drug, a number of investigators re-evaluated pamaquine. 
They confirmed its activity but found a level of toxicity which precluded its use 
In an effort to improve the therapeutic index of pamaquine, the U.S. Office 
of Scientific Research and Development (OSRD) supported the synthesis of 
hundreds of new 8-aminoquinolines [63-801. By the end of World War 11, this 
programme had produced pentaquine (5) [81-841. Following the war, the U.S. 
Public Health Service sponsored a programme from which emerged isopenta- 
quine (6), SN-3883 (7) and primaquine (8). Although compounds (5)-(8) were 
all better than pamaquine, it was the pressure of another war, the Korean 
conflict (1950-1953), which ultimately established primaquine (8) as the drug 
of choice for the radical cure of the relapsing malarias [85-93 1. 
[ 59-62]. 
NHR 
parnaquine (Plosrnochln) ( 4 )  R = CHMe(CH213NEt2 
(5) R = (CH2)5NHCHMe2 pentoquine 
(6) R = CHMe(CH2),NHCHMez isopentaquine 
(8) R = CHMe(CH2),NH2 pr i rnaquine 
(9) R = (CHz),CHMeNH2 quinocide 
S N  - 3883 (7) R = (CH&NH2 
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Quinocide (9), an isomer of primaquine, is used in Eastern Europe and the 
USSR but it is more toxic than primaquine [94-1011. Primaquine is presently 
the preferred radical curative drug in most parts of the world. The work leading 
from pamaquine to primaquine has been detailed in a number of reviews [ 11, 
12, 621. Primaquine has a broad range of antimalarial activity. In addition to 
its radical curative activity, primaquine is a causal prophylactic, a gametocyto- 
cide and a sporontocide. It can also be produced at low cost and has been 
relatively slow to select resistant strains [ 102-1041. Despite these attributes, 
primaquine is far from the ideal antimalarial. It is a poor blood schizontocide 
and, although it is the best of the 8-aminoquinolines, its clinical use as a tissue 
schizontocide is still limited by serious side-effects such as haemolysis, 
methaemoglobinemia and gastrointestinal distress. Particularly prone to 
haemolytic reactions are patients with a genetic deficiency of glucosed-phos- 
phate dehydrogenase (G-6-PD) [ 1051. Also troublesome is the need to admin- 
ister primaquine in divided doses over an extended period (15 mg daily for 14 
days) since, in addition to its toxicity, it is rapidly absorbed, metabolized and 
eliminated. Clinicians have therefore been using primaquine with some 
trepidation and with the desire for a safer, more effective congener. 
The most recent surge in antimalarial chemotherapeutic research started 
with the disturbing discovery in 1960 that P. falcipamm was becoming resistant 
to the major blood schizontocide, chloroquine [ 106-1081. In 1963, the U.S. 
Army Medical Research and Development Command (USAMRDC) initiated 
the Antimalarial Drug Development Program because resistant P. falciparum 
was endangering U.S. forces in Vietnam. This monumental program, coordi- 
nated through the Walter Reed Army Institute of Research (WRAIR), 
Washington, DC, has resulted in the primary screening of over 300,000 
compounds. From these compounds emerged a number of amino alcohol blood 
schizontocides, most notably mefloquine, which are relatively safe and pres- 
ently effective against resistant P. falcipamm. Amazingly, even though meflo- 
quine is not yet in general use, resistant cases have been observed in Thailand 
[ 1091 and in Tanzania [ 1 lo]. Thus, after 20 years of development, and while 
still in field trials, this cream of the blood schizontocidal crop is already under 
a cloud. 
The Vietnam experience also stressed the need for a better radical curative 
drug than primaquine [ 11 1-1 141. Accordingly, in 1968, the Army shifted its 
emphasis to the discovery of more effective, less toxic 8-aminoquinolines. In 
1975, the Army’s effort was bolstered by the initiation of the research program 
of the Scientific Working Group (SWG) on the Chemotherapy of Malaria 
(CHEMAL), organized by the UNDP/WORLD BANK/WHO Special Pro- 
gramme for Research and Training in Tropical Diseases (TDR) [ 1151. A third 
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source of funds, the U. S .  Agency for International Development, has concen- 
trated its support on vaccine development. In the interval since 1968, the 
USAMRDC has supported the synthesis of a great number of new amino- 
quinolines [ 116-1451. Another intensive effort to improve primaquine is under 
way in the People’s Republic of China [ 146-1591. The USAMRDC program 
has produced new primaquine derivatives which, in animal models, combine 
low toxicity and a remarkable dual efficacy as blood and tissue schizontocides. 
This research is continuing. 
METHODS FOR ANTIMALARIAL DRUG EVALUATION 
The methods devised to screen candidate compounds for antimalarial activity 
have been described in a number of detailed reviews: avian [ 11, 12, 160-1641, 
rodent [ 165-1691, simian [ 170-1731, human [ 174-1761 and in vitro [ 177-1801. 
An early avian model, P. relictum in canaries, led to the development of 
pamaquine [ 381. Other avian plasmodia, P. gallinaceum in chicks and 
P. lophurue in ducklings, were used for the mass screening of potential anti- 
malarials in the World War I1 programme and helped in the development of 
pentaquine [ 11,121. Although the avian plasmodia had provided some valuable 
information, they are quite different from mammalian species and they ulti- 
mately fell into disrepute as uncertain predictors of drug effects in humans. 
A major advance occurred with the isolation, in 1948, of a rodent plas- 
modium, P. berghei, in a wild African rat [ 1811. This parasite readily infected 
laboratory rats and mice and was soon the basis for a number of more reliable, 
standardized tests [ 182-1851. One ofthe tests, the Rane screen, [ 1851 has been 
used by the USAMRDC as a primary screen for over 300000 candidate 
antimalarials and has generated a number of promising new leads [ 291. Another 
important stride was the demonstration, by Schmidt in 1947, that infection with 
sporozoites of P. cynomolgi in rhesus monkeys is the biological and chemo- 
therapeutic counterpart of similarly induced infections with P. vivax in humans 
[24, 62, 1861. It was the P. cynomolgi-rhesus screen which pointed to prima- 
quine as a superior weapon against P. vivax [ 1871. The subsequent discovery 
that the South American owl monkey (Aotus trivirgatus) and the squirrel 
monkey (Samiri sciureus) were susceptible to P. falcipamm and P. vivux made 
it possible to carry out in vivo preclinical studies on human malaria [ 188-1901. 
However, the price and scarcity of monkeys have stimulated the search for 
in vitro screens which may eventually eliminate the need for preclinical testing 
in animals [ 177-1801. 
With antimalarials, as with all drugs designed for human use, the ultimate 
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screening animal is man. From 1917 to 1939, antimalarials were screened in 
volunteers and in patients with neurosyphilis who received therapeutic malaria 
for the beneficial effect of the induced fever [ 1911. The advent of penicillin 
caused a drastic drop in the number of neurosyphilitics and minimized the 
utility of malariotherapy as a screening device. Since 1939, clinical trials have 
been carried out in volunteers; particularly helpful during World War I1 and 
the conflicts in Korea and Vietnam were prison inmates and military personnel 
[ 11, 19,62, 192-1961. Public concern caused the discontinuation of the prison 
programme in 1975 and clinical trials are now conducted with paid civilian 
volunteers. 
The screens most relevant to the work discussed in this chapter are the Rane 
blood schizontocidal test (P .  berghei-mouse) [ 1851 and the Schmidt radical 
curative test (P. cynomolgi-rhesus) [ 23, 197, 1981 ; these are the preclinical 
screens most commonly used by the U.S. Army Antimalarial Drug Develop- 
ment Program. None of the promising new 8-aminoquinolines has reached the 
clinical stage. 
RANE BLOOD SCHIZONTOCIDAL SCREEN (P. BERGHEI INFECTION IN MICE) 
This simple model has served as the principal primary screening test for blood 
schizontocidal activity since 1964. It benefits from the genetic homogeneity of 
laboratory mice, their resistance to interfering bacterial and viral pathogens, 
their small body size, ready availability, ease of handling and low cost [ 1991. 
The Rane screen is highly reproducible and responds to a broad spectrum of 
chemical classes. It is based on a comparison of responses by groups of treated 
and control mice, five in each group, after infection with P.  berghei KBG 173. 
Utilizing young ICR/HA Swiss mice and a standard inoculum of P.  berghei, 
it is possible to produce a uniform disease fatal to 100% of untreated animals, 
within 6 to 8 days, with a mean survival time of 6.2 days. Test animals of 
approximately the same age and weight are housed in metal-topped plastic 
cages, given a standard laboratory diet and water ad libitum. The animals 
receive an intraperitoneal injection of 0.5 ml of 1 : 100 dilution of heparinized 
heart’s blood with a minimum of 90% parasitized cells (4 x lo7 cells), drawn 
from donor mice infected 1 week earlier with P. berghei. The donor strain is 
maintained by weekly passages in separate groups of mice inoculated with 
0.5 ml of 1 : 500 dilution of heparinized heart’s blood. Test compounds are 
administered after dissolution or suspension in peanut oil. A single dose is given 
subcutaneously 72 h after the mice are infected with P. berghei. At this time a 
10-15 % parasitemia has developed; the disease is well established, but has not 
produced sufficient debility to alter the response of the host to any toxic effects 
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of the test compound. Since treatment is withheld for 3 days and death occurs 
in untreated controls within 6-8 days, this system presents a candidate drug 
with the maximum challenge. In order to check factors such as changes in the 
infectivity of P. berghei or in the susceptibility of the host or to detect technical 
errors, a group of infected animals treated with pyrimethamine at dose levels 
producing definite increases in survival time is included as a positive control 
in every experiment. In each experiment, test compounds are administered in 
graded doses; 640, 160 and 40 mg/kg in the first series and, if activity warrants, 
640,320, 160,80,40 and 20 mg/kg in the second series. If activity is still evident, 
the dose is halved, stepwise, until activity disappears. With highly active 
compounds, increases in dose levels are usually followed by increases in the 
survival time of the treated mice. However, if an active drug is toxic for the host, 
its toxicity may become a limiting factor; a continued increase in dose levels 
also increases the toxic effects and may result in the diminution of survival 
times. Deaths prior to the 6th day, when untreated controls begin to die, are 
regarded as non-parasitic and become the basis for toxicity evaluation. A mean 
survival time twice that of the controls is evidence of activity and after 60 days 
survivors are considered cured. Toxic deaths and 60-day survivors are not 
included in calculating mean survival time. 
SCHMIDT RADICAL CURATIVE SCREEN (P. CYNOMOLGI INFECTION IN 
RHESUS MONKEYS) 
As noted earlier, sporozoite-induced cynomolgi malaria in rhesus monkeys 
(Macacu muluttu) is much like a vivax infection in man. I? cynomolg?s persistent 
tissue forms, resembling human hypnozoites, make it an excellent model for the 
evaluation of candidate radical curative drugs. Well-conditioned Indian rhesus 
monkeys of either sex, weighing 2-4 kg, are utilized. P. cynomolgi (Bastianelli 
strain) sporozoites are prepared by grinding heavily infected anopheles 
balabacensis salivary glands in 1 : 1 monkey serum-saline vehicle. Monkeys are 
infected by i.v. injection of lo6 freshly isolated P. cynomolgi sporozoites on day 
0. A rapidly rising parasitemia develops after a 7-9-day prepatent period, and 
administration of the test drug is initiated when the rising parasite count 
exceeds 5000 per mm3 (typically day 10-12). Test drugs are administered 
orally, by nasogastric intubation, once daily for 7 consecutive days in aqueous 
solution or, if insoluble, in suspension in 0.3 % methylcellulose solution. Chloro- 
quine diphosphate (3.1 mg/kg base orally per day) is always administered 
concurrently with the test drug for 7 days to eliminate blood schizonts. Thus, 
any tissue schizontocidal activity of the test drug will always be apparent even 
if it lacks blood schizontocidal activity. A vehicle control monkey and a positive 
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drug control (primaquine) monkey are included in each group of inoculated 
monkeys. The effect of the test drug is determined by counting blood parasites. 
Parasite counts are made daily through day 20 and every 2 days thereafter. 
Initially, a clearance of blood parasites is observed due to the blood 
schizontocidal action of chloroquine. If exoerythrocytic parasites (tissue 
schizonts) survive the action of the test drug, because it is inactive or marginally 
active, there will be a relapse of blood parasites. If there is no relapse within 
20 days of the initial clearance of parasitemia, parasitemia is followed for an 
additional 80 days. If there is no relapse within this period, the experiment is 
terminated and the monkey is considered cured. Primaquine diphosphate cures 
90% of monkeys in this test system when administered at a dose of 1.3 mg/kg 
per day for 7 days (1.0 mg/kg free base) in combination with chloroquine. 
In an early version of this screen, at the Southern Research Institute in 
Birmingham, Alabama, Schmidt used set drug doses of 10, 1, 0.75, 0.5, 0.25, 
0.125 and 0.0625 mg/kg. A subsequent version directed by John Brown and 
Frank Chapple of the SEAT0 Medical Research Group, Bangkok, Thailand, 
used doses of 10,3.16, 1.0,0.316 and 0.1 mg/kg. The same doses are at present 
being used by M.M. Dhar in the screen's most recent home in the Central Drug 
Research Institute, Lucknow, India. 
STRUCTURE-ACTIVITY RELATIONSHIPS 
Primaquine was itself the culmination of more than a half century of intensive 
research in the U.S.A., the United Kingdom, Germany, France and Russia. 
The determination of the U.S. Army Medical Research and Development 
Command to improve on primaquine therefore presented a daunting challenge. 
Fortunately, the earlier avian work [ 11, 121 had provided a useful pad from 
which to launch the new programme. Despite the multiplicity of avian models 
and the differences between avian and mammalian malarias, it was cautiously 
assumed that among the 8-(aminoalkylamino)quinolines (10): 
Me 
I 
CI 
c F3 
ch lo roqu ine  
me1 loqulne 
(a) A methoxy group at position 6 would elevate both activity and toxicity; 2-, 
4- and 5-methoxy groups would be less beneficial than the 6-methoxy 
group. 
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(b) The hydrogen, hydroxy, ethoxy, n-butoxy and hydroxyethoxy groups would 
be less effective at position 6 than the methoxy group. 
(c) The 2,6- and 5,6-dimethoxyquinolines and 5,6-methylenedioxyquinoline 
would be less active and less toxic than the corresponding 6-methoxy 
derivative, with toxicity decreasing more than activity for an increase in 
therapeutic index. 
(d) A 5-phenoxy group would reduce toxicity much more than activity, thus 
producing a high therapeutic index; a 5-phenyl group would eliminate 
activity. 
(e) One or more halogens at positions 3, 4 or 6 would diminish activity and 
toxicity. 
(0 The 5-,6- and 7-methyl groups would contribute little of value; the 4-methyl 
group would diminish toxicity without affecting activity; a pair of methyls 
at positions 2 and 4 would have about the same effect as a single methyl 
at position 4. 
(8) An amino or anilino group at position 5 of a 6-methoxyquinoline would 
reduce toxicity more than activity. 
(h) A 4-methylthio group or a 4-benzyl group would reduce activity and 
toxicity. 
(i) Saturation of the quinoline ring would reduce efficacy. 
6 )  A primary terminal amino group in the side-chain would be less toxic than 
a secondary or tertiary amino group; the aromatic 8-amino group should 
be secondary. 
(k) The number of methylene groups separating the 8-amino nitrogen atom and 
the terminal nitrogen atom of the side-chain should be greater than three 
to avoid the severe irreversible neurotoxicity of antimalarials like rhodo- 
quine (plasmocid); the optimal number of methylenes between nitrogen 
atoms would probably be 4-6. 
On this tentative basis and with the support of the new mammalian screens, 
major work on the design and synthesis of improved 8-aminoquinoline anti- 
malarials was undertaken in 1968, by the American teams of Blanton (Univer- 
sity of Georgia, Athens, GA), Carroll (Research Triangle Institute, Research 
Triangle Park, NC), LaMontagne (Ash Stevens, Inc., Detroit, MI) and Nodiff 
(Franklin Research Center, Philadelphia, PA). Additional synthetic contribu- 
tions were provided by Archer (Rensselaer Polytechnic Institute, Troy, NY), 
Cheng (Midwest Research Institute, Kansas City, MO), Klayman (Walter 
Reed Army Institute of Research, Washington, DC) and Werbel (Warner- 
Lambert/ Parke-Davis, Ann Arbor, MI). During the past decade a number of 
Chinese investigators have also entered the field (Institute of Parasitology and 
the Second Military Medical College, Shanghai; Military Academy of Medical 
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Sciences, Beijing). The new programme placed primary emphasis on 8-amino- 
quinolines in which the 6-methoxy group and the primaquine side-chain were 
held constant while the nature, number and position of ring substituents were 
varied. Extensive synthesis of side-chain variants of primaquine, in earlier 
programs, had produced none with a better therapeutic index than primaquine 
itself. 
2-SUBSTITUTED ANALOGUES OF PRIMAQUINE 
Blanton and co-workers assumed that the activity of the 8-aminoquinolines 
stemmed from their metabolic conversion to the labile 5,6-quinones and that 
these quinones could be stabilized by appropriate substitution at position 2 of 
the quinoline nucleus [122]. This group therefore embarked on a program 
which produced compounds (1 1)-(25) in Table I .  1. Also included in Table I. I 
are derivatives prepared in the laboratories of the Franklin Research Center 
(26) [ 1401 and the Second Military Medical College, Shanghai (27-37) [ 1511. 
Table 1.1. 2-SUBSTITUTED ANALOGUES OF PRIMAQUINE 
NHCHMe(CH2)JNH2 
Compound Compound 
No. R No. R 
11 PhCH,O 25 Me2N 
12 4-FC6H4CHZO 26 Me 
13 4-CIC6H4CH20 27 3-ClC6HdCH20 
14 2,4-Cl,C6H3CHZO 28 3,4-Cl&H,CH,O 
15 3-CF,C6H,CH,O 29 4-BrC,H4CH,0 
16 4-CF3C6H,CHz0 30 PhO 
17 4-MeOC6H,CH20 31 4-FC6H,0 
18 PhCH2S 32 4-CIC6H40 
19 4-CIC,jH,CH,S 33 2,4,5-C13C,HZO 
20 Me0 34 4-BrC6H40 
21 c1 35 4-MeC6H,0 
22 Et 36 piperidino 
23 CH, = CH 31 pyrrolidino 
24 NH2 
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In the Rane blood schizontocidal screen (P. berghei, mouse), the Blanton 
group’s lead compound (1 1) was slightly active and non-toxic at doses up to 
640 mg/kg [ 1221; primaquine was toxic at 160 mg/kg in the same screen. On 
learning that (1 1) was also active in the radical curative screen (P. cynomolgi; 
rhesus), Blanton’s group extended its work to include the substituted benzyloxy 
derivatives (12)-(17) and their sulphur isosteres (18, 19) [ 1191. All of the new 
compounds had toxic doses greater than 640 mg/kg in the Rane screen, but 
only (12), (14) and (19) had even marginal activity in the same model. In the 
radical curative screen, the best of the new analogues, namely, the 4-flUOrO (12) 
and 2,4-dichloro (14) derivatives were slightly less potent than primaquine. A 
final attempt to optimize this series provided Blanton with compounds 
(20)-(25) [ 1181. Unfortunately, the methoxy (20), chloro (21), vinyl (23) and 
dimethylamino (25) derivatives had lost all of primaquine’s radical curative 
activity while retaining its toxicity; no data were available for the m i n e  (24). 
The ethyl derivative (22), a weak, non-toxic blood schizontocide, was also 
inactive in the radical model. Addition of a 2-Me group to primaquine to give 
(26) resulted in a small increase in radical curative activity and an attenuation 
of acute toxicity (1/5 toxic deaths ( T )  at 320 mg/kg vs. 2/5T at 160 mg/kg for 
primaquine). Stimulated by this work, Xu’s group prepared compounds 
(27)-(37) and resynthesized (11) and (13) [ 1511. The most effective member 
of the Chinese series, the phenyl ether (30) was only as effective as primaquine 
for the radical cure of cynomolgi malaria in the monkey. Thus, introduction of 
a lone substituent at position 2 of primaquine offers, at best, a small improve- 
ment in therapeutic index for the radical cure of malaria. 
3-SUBSTITUTED ANALOGUES OF PRIMAQUINE 
There is a dearth of information on primaquine with a single substituent at 
position 3. 3-Methylprimaquine [ 1401 is a little more toxic than primaquine 
(1/5T at 80 mg/kg vs. 2/5T at 160 mg/kg) and considerably more toxic than 
2-methylprimaquine (1/5T at 320 mg/kg) [ 1401; it has insignificant activity in 
the blood schizontocidal screen and is slightly better than primaquine in the 
tissue schizontocidal model (2/2 cures ( C )  at 1.0 mg/kg vs. 1/2Cfor primaquine 
at the same dose). 3-Methylprimaquine is a powerful causal prophylactic in the 
mouse model [23]. 
4-SUBSTITUTED ANALOGUES OF PRIMAQUINE 
4-Methylprimaquine ((38); Table I .2), a promising antimalarial originally pre- 
pared by Elderfield, et al. in the World War I1 programme [ 801 was resynthe- 
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sized by Nodiffs group for evaluation in the new mammalian screens. This 
analogue was somewhat superior to primaquine as a radical curative and blood 
schizontocidal agent and less acutely toxic in mice [ 1401. However, the sub- 
acute oral toxicity of 4-methylprimaquine in dogs and monkeys was prohibi- 
tively greater than that of primaquine [ 2001 and work on (38) was discontinued. 
In an effort to improve the therapeutic index of (38), additional ‘!-mono- 
substituted primaquines (Table 1.2) were prepared by Carroll et al. [ 1281 
Table 1.2. 4-SUBSTITUTED ANALOGUES OF PRIMAQUINE 
R 
”^ ”* 
N H C H M F ( C H ~ ) ~ H ~  
(38) - (66) 
Compound 
No. R 
Compound 
No. R 
38 
39 
40 
41 
42 
43 
44 
45 
46 
41 
48 
49 
50 
51 
52 
Me 
Et 
CH, = CH 
Pr 
Bu 
EtCH(Me)CH, 
C6H 1 I CHZ 
C6H1 
MeCH = CH 
EtCH = CH 
C6HllCH = CH 
cis-MeCH = CH 
4-FC6 H4 SCH, 
4-ClC,z,H,S(CH,), 
4-MeOC6H4S( CH,), 
53 
54 
55 
56 
51 
58 
59 
60 
61 
62 
63 
64 
65 
66 
Me0 
MeS 
NH, 
CH,CONH 
MeNH 
OH 
4-MeOC6H,O 
4-CIC6H40 
3,4-C1,C6H,O 
3-CF,C,H,O 
4-CLC6H4NH 
4-CIC6H4S 
4-MeOC6H,S 
4-CIC6H4CHZO 
(39-52), and LaMontagne et al. [ 1391 (53-66). Of moderate interest among 
these compounds were (39), (40) and (59). In the blood schizontocidal screen, 
the ethyl (39) and vinyl (40) derivatives were slightly less active than primaquine 
at doses up to 80 mg/kg and were less toxic than primaquine at the higher doses. 
The ethyl derivative, the better of the two, was non-toxic over the range 
20-640mg/kg and it was 40% and 100% curative at 320mg/kg and 
640 mg/kg, respectively. In the radical curative test, the ethyl derivative was as 
active as primaquine and the vinyl compound was slightly less active. The 
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4-C1C,H4O derivative (59) was 60% curative in the Rane screen at 160 mg/kg 
and 100% curative at 320-640 mg/kg. However, in contrast to the ethyl (39) 
and vinyl (40) analogues, the phenoxy derivative (59) was devoid of radical 
curative activity at the highest dose tested (10 mg/kg). 
It now seemed clear that monosubstitution on the pyridine ring of primaquine 
would, at best, attenuate acute toxicity without the desired concomitant 
enhancement of radical curative activity. Additional work at positions 2,3 and 
4 was therefore held in abeyance. 
5-SUBSTITUTED ANALOGUES OF PRIMAQUINE 
The most effective 8-aminoquinoline to emerge from the earlier avian com- 
pilation [ 121 was the 5-aryloxy derivative (67). This compound had a thera- 
peutic index of 177 compared with 57 for pentaquine (5) and 30 for primaquine 
(8). With (67) as a lead, Nodiffs group prepared the various 5-phenoxy-, 
5-phenylthio- and 5-anilinoprimaquines (68-88) [ 142, 144, 1451 shown in 
Tabk 1.3. Prompted by this work, Zheng et al. resynthesized (69), (70), (71) 
and (74) and added the new analogues, (89)-(92) [ 1591; Xuet al. resynthesized 
(68), (69), (70), (73), (89) and (90) and introduced (93)-(98) [ 149, 1561. 
All of the compounds in Table I .3 were less toxic than primaquine in the 
murine blood schizontocidal screen. With the exception of (72), none produced 
acute lethality at the highest dose tested (640 mg/kg); (72) caused a single death 
at this dose. The most active blood schizontocides in Table 1.3 were the 
fluorine-containing derivatives, 4-flUOrO (70) and 3-trifluoromethyl(7 l), which 
were completely curative at 320 and 640 mg/kg, respectively. The compound 
containing both 4-F and 3-CF3 (77) was less active (2/5C at 640 mg/kg) than 
either of the single substituted derivatives. The 4-Me0 derivative (73), closely 
related to the lead compound (67), was almost equipotent (4/5C at 640 mg/kg) 
with (71). The best of these compounds in the radical curative test (70), (71) 
and (77) were slightly more active than primaquine. The most interesting 
compound among the Chinese contributions was the resynthesized analogue 
(70). Zheng et al. [ 1591 reported that, against P. yoelii in the mouse, (70) was 
20-times less toxic and 4-5-times less effective than primaquine. According to 
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Table 1 3  5-PHENOXY, 5-PHENYLTHIO AND 5-ANILINO ANALOGUES O F  PRIMA- 
QUINE 
M e o w  
NHCHMe(CH21,NH 
Compound 
No. X R 
Compound 
No. X R 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
NH 
NH 
S 
s 
S 
H 
4-CI 
4-F 
3-CF3 
4-CF3O 
4-Me0 
2,4-CI2 
3,4-C12 
3,5-(CF,)z 
4-F-3-CF3 
4-MeCONH 
4-CI 
3-CF3 
2-CI 
3-CI 
4-CI 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
s 
s 
S 
S 
S 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3,4-CI2 
2,5-C1, 
4-Me0 
3,4-benzo 
4-Br 
4-Me 
4-1 
2-c1 
3-F 
3-c1 
3-Br 
3-Me 
3,4-Me, 
3,5-Me2 
3-CF3 
Zheng et al. the fluorophenoxy (70) was also less effective than primaquine 
against P. cynomolgi in the monkey. 
All of the anilino and phenylthio derivatives (79)-(88) were nontoxic and 
inactive or very weakly active at 640 mg/kg in the blood schizontocidal screen. 
In the radical curative screen, the entire phenylthio series (81)-(88) was cura- 
tive at 10mg/kg but only the 4-chloro (83) and 3-trifluoromethyl (87) 
compounds were curative at 1 mg/kg. The anilino derivative (80) was inactive 
even at 10 mg/kg. Thus, acute toxicity of primaquine can be diminished by 
introduction of various phenoxy, phenylthio or anilino groups at position 5. The 
phenylthio and anilino analogues were consistently less active than their oxygen 
isosteres, but all three series were unimpressive. There is a notable difference 
between the 4- and 5-phenoxyprimaquines. While the 5-phenoxy derivatives 
showed moderate radical curative activity in the monkey, the corresponding 
4-phenoxy derivatives were inactive at the highest dose tested. In contrast, the 
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4-phenoxy derivatives were more potent blood schizontocides than their 
5-phenoxy counterparts. Neither group was active in the mouse prophylactic 
screen. 
The lead compound (67) was resynthesized by Kalidas and Blanton [ 1201. 
It is ironic that this compound, which had seemed so promising in the avian 
model and which had inspired so much additional research, was a total failure 
in the mouse and monkey screens. 
5-Methoxyprimaquine (99) had a similar radical curative activity to prima- 
quine and was slightly less toxic ; it lacked blood schizontocidal activity. With 
continuing interest in substitution at position 5, Nodiffs group prepared the 
higher homologues of (99) shown in Table 1.4 [ 140,1411. The best combination 
of blood schizontocidal activity and nontoxicity occurred in the n-decyl deriva- 
tive (107). However, this compound was relatively unimpressive with only two 
cures at 640 mg/kg. On moving from R = decyl down through the homologous 
series, acute toxicity gradually increased until, when R was butyl or smaller, 
toxicity was greater than that for primaquine itself. The toxicity increase at the 
higher doses (80-640 mg/kg) was not accompanied by any elevation in activity 
at the lower end of the dosage range. With the exception of the n-decyloxy 
derivative (107), which was radically curative only at 10 mg/kg, all of the 
compounds in Table 1.4 were completely curative at 1.0 mg/kg. Among these, 
the propoxy (102), butoxy (103) and pentoxy (104) derivatives were also cura- 
tive at 0.3 16 mg/kg, making them somewhat more active than primaquine (1/2C 
at 1.0 mg/kg). 
At this juncture, the 5-phenoxyprimaquines seemed more promising than 
their excessively toxic 5-alkoxy analogues. 
Table 1.4. 5-ALKOXY DERIVATIVES OF PRIMAQUINE 
Meom N H C H M ~ C H ~ ) ~ N H ~  
(991 -(lo71 
Compound 
No. R 
Compound 
NO. R 
99 Me 
100 Et 
101 CF,CH, 
102 n-Pr 
103 n-Bu 
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2,4-DISUBSTITUTED ANALOGUES OF PRIMAQUINE 
Recognizing the limited ability of a single substituent to improve primaquine's 
therapeutic index, various investigators introduced more than one. The 
2,4-disubstituted analogues (log)-( 1 lo), prepared by Carroll et al. [ 1271 and 
shown in Table 1.5, were less toxic and less active than primaquine in the blood 
schizontocidal screen (no cures or toxic deaths at 640 mg/kg). Primaquine and 
(108) were equally active as tissue schizontocides. 
Table I .5. 2,4-DISUBSTITUTED ANALOGUES OF PRIMAQUINE 
-=Ow N H C H M F ( C H ~ ) ~ N H ~  R2 
(108) - (1101 
Compound 
No. R' R2 
108 Me Et 
109 Me CH, = CH 
110 Et Me 
2,5-DISUB STITUTED ANALOGUES OF PRIMAQUINE 
Nodiff and co-workers found that the 2-methyl derivative of 5-(n-hexyloxy)- 
primaquine (1 11) had slightly greater blood schizontocidd activity than its 
parent compound (105), at doses from 20 to 160mg/kg (3C vs. 1C at 
160 mg/kg) and was more toxic at 320-640 mg/kg (3T vs. 1T at 640 mg/kg). 
The radical curative difference between (105) and (1 11) was slight [ 1401. It is 
of interest that 5-(n-hexylthio)-2-methylprimaquine (1 12), the sulphur isostere 
of (lll), was a somewhat better blood schizontocide than (111) with 3C at 
160 mg/kg and 5C at 320-640 mg/kg (unpublished data). 
(CH,),Me 
I 
" ' O W  Me 
NHCHMe(CH2)JNHi  
(111) x = 0 
(112)  x =  s 
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Xu and Xu [149] and Zheng and Cheng [152] prepared the series of 
2,5-disubstituted primaquines (1 13-1 19) shown in Table I .6. The fluorine 
derivative (1 13) showed some activity against sporozoite-induced infection by 
P. yoelii in mice. 
Table 1.6. 2,5-DISUBSTITUTED ANALOGUES OF PRIMAQUINE 
OC6H4R 
I’ 
“‘Om OC&R 
NHCHMe(CHZ),NH2 
(113)-(119) 
Compound Compound 
No. R No. R 
113 4-F 
114 4-Br 
115 4-CI 
116 3-CF3 
1 I7 4-Me 
118 4-Me0 
119 H 
4,5-DISUBSTITUTED AND 2,4,5-TRISUBSTITUTED ANALOGUES OF 
PRIMAQUINE 
After the extensive, above-detailed exploration of peripheral veins by various 
groups, the teams of Nodiff and LaMontagne seemed to strike the mother lode 
(or guiding principle). These investigators found that addition of a 4-methyl 
group to unimpressive 5-aryloxy- or 5-alkoxyprimaquines produced dramatic 
antimalarial enhancement. As detailed below, some of these 4-methyl 
compounds are unique in their combination of very low acute toxicity and 
wide-ranging activity as blood schizontocides, radical curative drugs and 
causal prophylactics. 
Table I .  7 includes various members of this series prepared by LaMontagne 
etal. (120)-(124) [134, 1361, Nodiff etal. (125)-(131) 11421, (129)-(131) 
(unpublished data), Carroll et al. (132)-( 137) [ 1251, Deng et al. (138)-( 140) 
[ 1531 and Wang and Xu (141) [ 1501. Deng resynthesized (120), (121) and (123) 
and Wang resynthesized (124). Blood schizontocidal and radical curative data 
for the most effective compounds in this series are compared (in Table 1 .S) with 
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Table 1.7. 4-ALKYL-5-(ARYLOXY)PRIMAQUINESa 
"eowR;l 
N' R3 
NHCHMe(CH2)3NH2 
(1 201 - (1 41 0) 
No. R' R2 No. R' R2 
120b 3-CF3 4-Me 132 3-CF3 4-Et 
121 2,4-C12 4-Me 133 3-CF3 4-CH2 = CH 
122 3,4-C12 4-Me 134 3-CF3 4-CHzOH 
123 4-Me0 4-Me 135 3-CF3 4-MeOCH, 
1 24 4-F 4-Me 136 3-CF3 4-(MeO),CH 
126 4-F-3CF3 4-Me 138 4-Me 4-Me 
127 4-F-3CF3 3-Me 139 4-Me3C 4-Me 
128 3,5-(CF,)2 4-Me 140 2,4,5-C13 4-Me 
129 4-Et0 4-Me 141 3-F 4-Me 
130 4 - ( G H ,  1 )  4-Me 141a' 3-CF3 4-Me 
131 4-Ph0 4-Me 
a In compounds (120)-(141), R3 = H; in compound (141a), R3 = MeO. 
125 H 4-Me 137 3-CF3 4-(3-CF,C,H,OCHz) 
WR-225,448. 
WR-238,605. 
corresponding data for primaquine. All of the 4,Sdisubstituted derivatives in 
Table 1.8 were considerably less toxic than primaquine and much more active 
in both the blood schizontocidal and radical curative screens. The 3-CF3 and 
4-F derivatives (120, 124) were equally active in the blood screen (multiple C 
at 10 mg/kg) and in the radical screen (2/2C at 0.316 and 1.0 mg/kg; no C at 
0.1 mg/kg) and displayed little toxic lethality below 640 mg/kg. The 3,4-C1, 
analogue (122) was a more effective, less toxic blood schizontocide (80% 
curative at 5 mg/kg; 100% curative at 10-640 mg/kg) than (120, WR-225,448) 
or (124) but it was slightly less active than these compounds in the radical 
model (1/2C at 0.3 16 mg/kg). The phenyl-unsubstituted derivative (125) was 
more toxic than the other members of this series (3/5T at 320-640 mg/kg) but 
it was the only one to effect any radical cures at the low dose of 0.1 mg/kg. Most 
of the high blood schizontocidal and radical curative activities and the low 
toxicity of (120) were retained when its 4-methyl group was replaced by an ethyl 
(132) or methoxymethyl (135) group. However, replacement of the methyl 
of (120) with a CH, = CH (133), CH,OH (134), (MeO),CH (136) or 
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Table 1.8. ANTIMALARIAL ACTIVITY AND TOXICITY OF 4-METHYL-5-(ARYLOXY)- 
PRIMAQUINES 
See formula in Table 1.7. 
Blood schizontocidal activitya P. berghei, mouse; dose, 
mglkg; cures (C)b. toxic deaths (TJC or AMSTd 
Radical curative 
activitye 
P. cynomolgi, 
rhesus; dose, mglkg; 
cureslNo. of animals 
No. R’ 5 10 20 40 80 160 320 640 0.1 0.316 1.0 
(8) (Primaquine) 4.0 5.0 9.4 2T 5 T  5 T  012 012 112 
120‘ 3-CF3 6.9 2C 5C 5C 5C 5C 5C IC ,4T  012 212 212 
122 3,4-CI, 4C 5C 5C 5C 5C 5C 5C 5 c  013 112 313 
123 4-Me0 5.5 5.9 1C 5C 5C 5C 5C 2C, 3T 012 212 313 
124 4-F 7.0 3C 4C 5C 5C 5C 4C, I T  3C ,2T  013 212 313 
125 H 8.7 4C 3C 4C 4C 3T 3T 112 111 212 
a Activities were determined at the Rane Laboratory, University of Miami, Florida, with five 
mice per group, via the method of Osdene etal. [185]. 
The number of mice surviving at 60 days post-infection. 
Deaths prior to the 6th day. 
Increase in mean survival time over controls (MST of control group, 6.1 days). 
Tests were carried out by the SEAT0 Medical Research Laboratory, Bangkok and the Central 
Drug Research Institute, Lucknow, according to the procedure of Schmidt et al. [197]. 
R” = 4-Me and R3 = H for compounds (120), (122)-(125). 
3-CF,C6H,OCH, (137) banished radical curative activity and either eliminated 
or severely depressed blood schizontocidal activity. 
On the basis of blood and tissue data, (120) was judged the most promising 
member of the series and was selected by the USAMRDC for additional 
preclinical evaluation [134, 1361. In a repetition of the Rane blood 
schizontocidal test, which used more than the usual five mice at several concen- 
trations, (120) effected 10/1OC at 160mg/kg and 20mg/kg and 15/15C at 
40 mg/kg but only 2/10C (4 toxic deaths) at 640 mg/kg. Primaquine and (120) 
were also compared for suppressive activity against P. cynamolgi in the rhesus. 
This test differs from the radical curative test in that parasitemia is induced by 
intravenous inoculation of parasitized blood rather than by sporozoites and 
that chloroquine is not co-administered with the test drug [201]. Primaquine 
was suppressive but did not completely clear blood schizonts at doses from 1.0 
to 31.6 mg/kg per day ( x 7); (120) was 100% curative at 1.0 mg/kg per day 
( x 7) and was suppressive but not curative at doses as low as 0.0316 mg/kg. 
E.A. NODIFF, S. CHATTERJEE AND H.A. MUSALLAM 23 
As mentioned earlier, the toxicity of primaquine precludes administration of 
a single radically curative dose; in order to achieve radical cure of P. vivax in 
man, multiple doses are required coupled with the blood schizontocide, chloro- 
quine. Accordingly the radical curative screen (P.  cynomolgi - rhesus) was 
modified to establish whether a single dose of (120) was effective as both a 
tissue and blood schizontocide and whether the co-adminstration of chloro- 
quine was necessary. This test showed that primaquine was effective in two of 
four monkeys at 3.5 mg/kg ( x  1) but permitted 2/2 relapses at 1.75 mg/kg; its 
fully curative dose was 14 mg/kg ( x 1). Prirnaquine and (120) were about 
equally active at 3.5 mg/kg without chloroquine, but in the presence of chloro- 
quine the fully curative dose of (120) dropped to 0.875 mg/kg ( x 1) compared 
to 14mg/kg ( x  1) for prirnaquine; (120) permitted 4/4 relapses at 
0.4375 mg/kg. Acute toxicity evaluation in rats and guinea-pigs indicated that 
(120) was less toxic than primaquine by factors of 1.5-3.2. 
Causal prophylaxis, originally attributed to residual blood schizontocidal 
activity, was confirmed in the Most model [25, 1831. Against a trophozoite- 
induced vivax infection in the Aotus trivirigatus monkey, (120) was 100% 
curative at a total dose of 12 mg/kg, while primaquine was non-curative even 
when the total dose was raised to 160 mg/kg [201]. 
However, the elation elicited by the accumulating positive data for (120) was 
short-lived. In subacute (60 day) studies with rats, (120) was more toxic than 
primaquine. Clinical chemistry alterations and tissue lesions were induced by 
(120) which were not seen when primaquine was administered at equal doses 
[25]. Of particular concern was the haematotoxicity of (120). A general defi- 
ciency of the 8-aminoquinolines is their tendency to produce methaemo- 
globinemia [ 202-2101. This condition is characterized by a concentration of 
methaemoglobin (MHb) in erythrocytes which is greater than the usual 1 to 
2%. In methaemoglobin, the normal ferrous iron has been oxidized to the ferric 
state and is incapable of transporting oxygen. Methaemoglobinemia can thus 
lead to anoxia and death. According to Anders et al. [211], (120) induced in 
dogs a peak methaemoglobin level which was 4-times higher than that produced 
by primaquine (25.3% vs. 6.3% ; Table 1.9). 
Seeking to improve (120), LaMontagne et al. returned to the old avian 
literature and Mislow’s report that a 2-methoxy substituent reduced the toxicity 
of primaquine [64]. This led to the synthesis of (141a, WR-238,605), the 
2-methoxy derivative of (120) (Table 1.9) [ 1321. Compound (141a) had better 
blood and radical curative activities than its 2-demethoxy parent with no 
change in acute toxicity but with a third less methaemoglobin induction (16.0% 
vs. 25.3%; Table 1.9) [ 132, 133, 2111. It was also significantly less toxic than 
(120) in the rat either by oral or intraperitoneal administration [132, 1331. 
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Table 1.9. EFFECT OF THE 2-METHOXY GROUP ON THE ACTIVITY, ACUTE TOXI- 
CITY AND METHAEMOGLOBIN INDUCTION OF (120) 
See formula in Table 1.7. 
Blood schizontocidal activitya 
P.  berghei, mouse: dose, mglkg: cures 
(C)b. toxic deaths (T)' or AMSF 
No. 20 40 80 160 320 640 
(8) (Primaquine) 4.0 5.0 9.4 2T 5T 5 T  
(120)9 1c 4 c  5c 5c 5c 4C,1T  
(141a) 3c 5c 5c 5c 5c 4C,1T 
Radical curative activi- 
ty' P. cynomolgi, 
rhesus: dose, mglkg; 
cureslNo. of animals 
0.1 0.316 1.0 MHb' 
Peak % 
0/2C 0/2C 1/2C 6.3 
0/2C 2/2C 2/2C 25.3 
2/4C 4/4C 2/2C 16.0 
~ 
a-e See Table 1.8. 
Anders et al. [21 I ]  performed these evaluations on beagle dogs at the Walter Reed Army 
Institute of Research, Washington, DC. 
g The data reported by LaMontagne for (120), for this comparison [132], were somewhat 
different from those reported by LaMontagne for the same compound in an earlier study (Cpd 
(120) in Table 1.8) [136]. 
Against trophozoite-induced infections of the Chesson strain of P. vivax in the 
Aotus monkey, (141a) was slightly better than (120) (2/2C vs. 1/3C at 
1 mg/kg x 3) but it was somewhat less effective than (120) as a causal 
prophylactic against sporozoite-induced P. berghei yoelii in the mouse (0/5C vs. 
6/15C at 2.5 mg/kg, subcutaneously) [ 1331. Replacement of the 2-methoxy of 
(141a) with e l ,  OH, 4-C1C6H40 or 4-C1C6H4CH,O gave compounds which 
were inactive and non-toxic in the Rane screen and were not examined further 
[ 132, 1331. Compound (141a) is at present completing advanced preclinical 
evaluation. 
4-A Ikyl-5-(alkoxy)primaquines 
Concurrently with their research on the 4-Alkyl-5-(aryloxy)primaquines, Nodiff 
and co-workers prepared the substituted 5-(alkoxy)primaquines included in 
Table 1.10 (142-156, 158-170) [ 140, 1411. Additional analogues were synthe- 
sized by LaMontagne et al. (157, 171-174) [ 1371 and Carroll et al. (175, 176) 
[ 1243. R' in Table 1.10 encompasses n-alkyl, isoalkyl, cycloalkyl, alkenyl, 
cycloalkylmethyl, phenoxyalkyl, alkoxyalkyl, benzyloxyalkyl and phenylalkyl 
groups; work on the phenylalkoxy series (167)-(170) has not yet been pub- 
lished. 
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Table 1.10. 4-METHYL-5-(ALKOXY)PRIMAQUINES 
M e o w  R2 
NHCHMe(CH2)3NH2 
(142) -(176) 
No. R' R2 No. R' R2 
142 
143 
144 
145 
I46 
147 
148 
149 
150 
151 
152 
153 
I54 
155 
156 
157 
158 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
3-Me 
2-Me 
3-Me 
3-Me 
2,4-Me, 
2-Me0,4-Me 
4-Me 
159 PhO(CH,), 
160 PhO(CH,), 
161 C6H,,CH2 
162 Cyclopentyl 
163 CH, = CH(CH,), 
164 Me(CH,),O(CH,), 
165 MeO(CH,), 
166 PhCH,O(CH,), 
167 Ph(CH,), 
168 Ph(CH2)S 
169 Ph(CH& 
170 Ph(CH,), 
171 Me 
172 Me 
173 5,6-OCH,O- 
174 5,6-O(CH,)zO- 
175 Me 
176 Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
4-Me 
2,4-Me, 
4-Me 
4-Me 
4-CH2 = CH 
4-(m-CF,PhOCHZ) 
Among these compounds, introduction of a 4-methyl group to the shorter 
chain (c3-c8) 5-alkoxyprimaquines (142-147) generally produced a 
pronounced blood schizontocidal increase in the lower part of the dosage range 
and elevated acute toxicity at the higher doses (160-640 mg/kg). There was a 
progressive diminution in toxicity with increased chain length; the C, derivative 
(142) caused three toxic deaths at 40 mg/kg, while the c8 derivative (147) 
caused only two deaths at 640 mg/kg. The long-chain members of the series 
(C9-C12; 148-151) were responsible for no toxic deaths even at 640 mg/kg. 
Among the latter group, activity was inversely relafed to chain length, with the 
nonyl derivative (148) producing 2/5C at 10 mg/kg while its dodecyl homologue 
(151) only provided multiple cures (4/5C) at 160 mgfkg. The most promising 
members of this series were 4-methyl-5-(n-pentoxy)primaquine (144) and 
4-methyl-5-(n-hexyloxy)primaquine (145). Both of these compounds were cura- 
tive in the Rane screen at the extremely low dose of 2.5 mg/kg. Their activity 
in the radical curative screen was also extraordinary, with the pentoxy 
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compound (144) curing 3/4 monkeys at 0.1 mg/kg and its hexoxy analogue 
(145, WR-242,5 1 1) curing 5/5 monkeys at the same low dose. Compound (145) 
also displayed potent activity against P. berghei yoelii in the causal prophylactic 
screen, achieving 5/5Cat 10 and 40 mg/kg (subcutaneously), 3/5C at 2.5 mg/kg 
and 1/5C at 0.63 mg/kg. 
Unfortunately, both (144) and (145) were about as acutely toxic as prima- 
quine in the upper half of the dosage range of the Rane screen. Furthermore, 
the hexoxy derivative, (145) induced a worrisome methaemoglobin level in the 
dog(48.1% ~ 2 5 . 3 %  for(120)and 16.0% for(141a); Table1.9[211].Despite 
these drawbacks, the USAMRDC still considers (145) a viable antimalarial 
candidate because of its excellent blood schizontocidal activity (5/5C at 
20 mg/kg) and its unrivaled low-dose efficacy in the radical curative screen 
(5/5C at 0.1 mg/kg). The hexyl ether (145) is at present undergoing intensive 
preclinical evaluation. 
An effort to elevate the therapeutic index of (145), while retaining its dual 
activity, led to the synthesis of analogues (152)-(176) (Table 1.10) and per- 
mitted the following structure-activity correlations among the 5-(a1koxy)- 
primaquines. 
Blood schizontocidal activity 
(a) The 2-Me and 3-Me groups were almost equivalent and had a lesser effect 
on activity and toxicity than the 4-Me group (153 and 152 vs. 145). 
(b) Paired methyl groups at positions 2 and 4 contributed more to toxicity and 
less to activity than a single 4-methyl group (156 vs. 145). 
(c) Primaquines bearing a branched-chain alkoxy at position 5 were more toxic 
than their straight-chain isomer (154 and 155 vs. 152). 
(d) A 4-methylprimaquine with a 5-(unsaturated alkoxy) was less active and 
toxic than the corresponding saturated compound (163 vs. 143). 
(e) A 5-cycloalkoxy contributed less to activity and toxicity than the corre- 
sponding acyclic group (162 vs. 144). 
(0 Replacement of a terminal hydrogen, on a 5-alkoxy group, with a phenoxy 
moiety had little effect on the activity or toxicity of the resulting primaquine 
(g) Replacement of a terminal hydrogen, on a 5-alkoxy group, with an alkoxy 
diminished activity and increased toxicity (165 vs. 145). 
(h) The 5,6-bridged derivatives were either totally inactive (173) or highly toxic 
( 174). 
(i) Surprisingly toxic, with 2/5T at 20 mg/kg, was the benzyloxyhexyloxy 
derivative (166). This suggested the possibility that at least part of the 
(158-160 VS. 143, 145, 147). 
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toxicity of the 5-(alk0xy)primaquines stemmed from metabolic oxidation of 
the terminal methyl to a hydroxymethyl. With this in mind, NodifPs team 
protected the terminal methyl with the phenyl group producing the 
(167)-( 170) series (unpublished work). In each case, introduction of a 
phenyl group caused a striking reduction in toxicity with little or no decrease 
in activity. Comparative data for the 4-demethyl-5-(alkoxy)primaquines 
and the corresponding 4-methyl-5-(alkoxy) and 4-methyl-5-(phenylalkoxy) 
primaquines are grouped in Table 1 . 1 1 .  It should be noted that the 
5-(phenylheptyloxy) derivative (no), with 5 / 3 2  at 10-640 mg/kg and 2C 
at 5 mg/kg, is considerably more effective than mefloquine, the best of the 
new wave of blood schizontocides, which is curative at 20 mg/kg [212]. 
6)  As described earlier, LaMontagne et al. were able to upgrade a 4-methyl- 
5-(ary1oxy)primaquine (120) to (141a); (Table 1.9) by inserting an Me0  
group at position 2 [ 1321. An attempt to enhance (145) in a similar fashion 
was unsuccessful (157 vs. 145, Table 1.12)  [132]. The corresponding 
5-(phenylalkoxy) analogue (169, Table I .  11) was a better blood schizonto- 
cide than either (157) or (145). 
Radical curative activity 
(a) In moving through the homologous 4-methyl-5-(n-alkoxy)primaquines, 
from C, (145) to C,, (15 I), activity gradually decreased, with the C,, (149), 
C,, (150) and C,, (151) compounds non-curative at 1.0 mg/kg. 
(b) The 2,4-Me2 analogue (156) of (145) was only half as active as the parent 
compound (2/4C vs. 5/5C at 0.1 mg/kg) while the 3-Me (152) and 2-Me 
(153) analogues produced no cures at 0.1 mg/kg. 
(c) The 5-(phenylpentoxy) derivative (168, WR-254,715) and the 5-(phenyl- 
hexyloxy) derivative (169) were 100% curative at 0.316 mg/kg (4/4C); 
(168) also effected 1/2C at 0.1 mg/kg. 
(d) Among the few remaining compounds to achieve cures at 0.1 mg/kg were 
a 5-(phenoxyocty1oxy)primaquine (160) (1/2C), an analogue of (145) in 
which the 5-(hexyloxy) chain was interrupted by an oxygen atom (164) 
(1/3C) and the 2-Me0 derivative (157) of (145) (1/4C). 
It would thus seem that among the substituted 5-(alkoxy)primaquines, the 
best combination of low toxicity with high blood and tissue schizontocidal 
activity resides in 4-methyl-5-(phenylpentoxy)primaquine (168). 
Table 1.11. COMPARISON OF ANTIMALARIAL ACTIVITY OF 5-ALKOXY AND 5-(PHENYLALK0XY)PRIMAQUINES Nm 
M e o w  
NHCHMe(CH2)pZ 
Blood schizontocidal activitya P. berghei. mouse: dose, 
rnglkg: cures fC)b, toxic deaths (Tj' or AMSF 
Radical curative ac- 5 
tivitye P. cynomolgi, rl 
rhesus: close. mglkg; 
cures/No. of animals 
E 
F 
2 
3 
143 Me(CH,), Me 11.0 5C 3C 4 T  5T 5T 5T  012 2/2 l / l  r;: r 
B 
144 Me(CH,), Me 2C 5C 5C 4C 1C 2T  4T 5T 5T  314 212 ~ 0 
No. R' RZ 2.5 5 10 20 40 80 160 320 640 0.1 0.316 1.0 
8 (Primaquine) 4.0 5.0 9.4 2T 5T 5T 0/2 0/2 112 
38 (4-Me-Primaquine) 3.1 4.9 5.5 9.0 10.0 3C 0/4 212 
9 
103 Me(CH,), H 4.1 6.5 6.7 2T  3T 5T 214 212 * 
167 Ph(CH,), Me 7.6 2C 4C 4C 5C 3C 0.4 0.0 0/3 1/2 414 
104 Me(CH,), H 4.3 4.7 6.1 4.7 4T 5T 2T 012 1/2 111 
168 Ph(CH,), Me 1.9 3C 4C 5C 5C 5C 3C 1C 112 414 212 C 
2 
145 Me(CH,), Me IC 1C 1C 5C 5C 4C 3T 5T 5T  5/5 313 l / l  2 
105 Me(CH,), H 3.76.5 1C 1C 0.1 I T  0/2 313 $ 
169 Ph(CH,), Me 5.9 1C 3C 4C 4C 3C 3C 4C 012 414 212 
157 Me(CH,), 2-Me0-4-Me 10.5 2C 5C 4C 5T 5T 114 313 212 
146 Me(CH,), Me 
170 Ph(CH2), Me 
7.9 3C 3C 5C 4C 2C l T  5T 5T 012 212 414 
2C 5C 5C 5C 5C 5C 5C 5C 012 014 313 
a-e See Table 1.8. 
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MODIFICATION OF THE QUINOLINE HETEROCYCLE 
Reduction of the pyridine ring 
Encouraged by the high avian antimalarial activity of 8-(5-diethylamino- 
2-pentylamino)-6-methoxy- 1,2,3,4-tetrahydroquinoIine (tetrahydropamaquine) 
[ 111 Carroll et al. prepared the 1,2-dihydroprimaquines (177, 178) and the 
1,2,3,4-tetrahydroprimaquine (179) [ 1301. Mouse and monkey screening data 
for (177)-( 179) suggest that reduction of the pyridine ring in primaquine lessens 
or eliminates activity. 
(177) R = H. 3 . 4 - d o u b l e  bond 
(178) R = MeO, 3 . 4 - d o u b l e  bond 
(179) R I H 
Substitution of naphthalene for quinoline 
Archer et al. found that several naphthalene analogues (180,18 1) of primaquine 
showed little tissue schizontocidal activity in the P. cynomolgi screen [213]. 
OMe 
Substitution of acridine for quinoline 
Klayman and co-workers synthesized acridine derivatives, which may be con- 
sidered as a benzoprimaquine (1 82) and a 4-methylbenzoprimaquine (1 83) 
[214]. The demethyl derivative (182) was inactive as a blood schizontocide and 
curative in the radical model at 10 mg/kg. Both derivatives were ineffective at 
3.16 mg/kg and were thus less active than primaquine. 
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R 
NHCHMe(CH&NH2 
(182) R = H 
(183) R = M e  
Substitution of benzofuran for quinoline 
The benzofuranyl isostere of primaquine (184), synthesized by Johnson and 
Werbel[215], was ineffective as a blood schizontocide and was never evaluated 
in the P. cynomolgi-rhesus model. 
ENANTIOMERS OF PRIMAQUINE 
Primaquine is used clinically as a racemic mixture. It was therefore of interest 
to compare the ( + ) and ( - ) enantiomers with the racemate. After Carroll et al. 
resolved the mixture [ 1291, Schmidt et al. studied the comparative antimalarial 
activities and toxicities of the racemate and its enantiomers in mice and rhesus 
monkeys [ 2161. According to the latter authors the ( + ) enantiomer was 4-times 
more toxic than the ( - ) enantiomer in mice but 3-5-times less toxic than the 
( - ) form in the rhesus. The radical curative activity of the racemate and its 
enantiomers against P. cynomolgi-rhesus was essentially the same. Assuming 
that the rhesus data were more predictive for man than the mouse data, 
Schmidt et al. concluded that the ( + ) form had a 2-fold advantage in thera- 
peutic index over primaquine and suggested clinical evaluation of this enan- 
tiomer against P. vivux; this has yet to be done. 
CHEMISTRY 
Typical syntheses are outlined in Schemes I. 1-1.3. 
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OMe OMe 
Phth r O A r  Me 
A r  = 3-CF3C6Hq kHCHMe(CH&NPht h NHCHMe(CH&NH2 
(120) 
Scheme 1 . 1  Compound (120) (Tables 1.7-1.9) /134.  1361. For Ar. Phth see lower leji corner. 
CONCLUSION 
Primaquine, the best available tissue schizontocide, suffers from a number of 
serious deficiencies. The concentrate of a 25-year search for an improved tissue 
schizontocide is the trio of new 8-aminoquinolines compared with primaquine 
in Table 1.12. All three are at least 10-times more effective than primaquine in 
the radical curative screen; (145), the best of the three in this screen, is 100% 
curative at 0.1 mg/kg. Quite unexpectedly, these compounds are also extremely 
effective blood schizontocides, with (168) providing multiple cures at 10 mg/kg. 
(The minimum curative dose for mefloquine, the best of the new blood 
schizontocides, is 20 mg/kg ; mefloquine has no radically curative activity.) 
Despite some uneasiness over the tendency of these drugs to produce 
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OAr M e  OAr M e  
M e o w  :hntnhyodlyilcdet xy lene  " ' O m  3-CICsH4COOH, C C13 
NPh th  
0- 
POCI3 
C H C l j  
NH2 
( See Scheme 1 1 1 
I 
OAr M e  OAr M e  
MeOH.NoH NH2NH2.H20 Meow 
CI MeowoMe NH2 Meowcl NH2 - EtOH NPhth 
tnree steps 
Scheme 1 1 
I "  
OAr M e  
CH2COOH 
CH2COOH 
OMe 
(1410) 
Scheme 1.2 Cornpound (141a) (Table 1.9) [132. 1331. Abbreviations as in Scheme 1.1.  
OH M e  
HMPT. E t j N  
c 
propylene oxide + n-C6H,3Br 
I 
N 4 
(Scheme 7 7 )  
(CHZ),Me 
I 
i two  steps 
HC-COOH 0s i n  Scheme 1 1  
' HOOC-:H 2 I u m o r i c  ocid 
NHCHMe(CH,),NH, 
Fe f i l i n g s  
HOAc. H20, B u l O  1 
(145) 
Scheme 1.3 Compound (145) (Tables 1.10, 1.11) 1140, 1411. 
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Table 1.12. ANTIMALARIAL ACTIVITY, ACUTE TOXICITY AND METHAEMOGLO- 
BIN INDUCTION OF COMPOUNDS (141a), (145), (168) AND PRIMAQUINE 
OR1 Me 
M e o ~ R 2  
Blood schizontocidal activitya Radical curative 
P. berghei, mouse :dose, mglkg; cures 
(C)b, toxic deaths (T)", AMSTd 
activity' 
P. cynomolgi, 
rhesus; dose, 
w l k g ;  
cureslhro. of 
animals 
Peak % 
No. Ri R2 10 20 40 80 160 320 640 0.1 0.316 1.0 MHb' 
(8) (Primaquine) 4.0 5.0 9.4 2T 5T 5T 012 012 112 6.3 
(141a)3-CF,C6H4 Me0 3 C  5C 5C 5C 5C 4C, I T  214 414 212 16.0 
(145) n-C,H,, H 1C 5C 5C 4C 3T 5T 5T 515 313 111 48.1 
(168) Ph(CH,), H 3C 4C 4C 5C 5C 3C 1C 112 414 212 
a-f See Table 1.9. 
methaemoglobinemia, (141a) is about to enter Phase I clinical evaluation and 
an application is being prepared for IND approval of (145). Compound (168) 
with an excellent primary profile, is still awaiting methaemoglobin evaluation. 
These broad spectrum antimalarials offer the possibility of a single drug that 
would be effective against all of the relapsing and non-relapsing malarias. 
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